EPIX Pharmaceuticals appoints interim CEO
This article was originally published in Scrip
Executive Summary
EPIX Pharmaceuticals (US), a biopharmaceutical company discovering and developing therapeutics through the use of its in silico drug discovery platform, has appointed Dr Elkan Gamzu interim chief executive officer, following the resignation of Dr Michael Kauffman as CEO and a director. Dr Gamzu is currently a consultant to the biotechnology and pharmaceutical industries and has held a number of senior executive positions in them.